A Platform For Advanced AAV Analytics

Accurate characterization of adeno-associated virus vectors is critical to advancing gene therapy development, yet traditional analytical methods often struggle to balance depth, speed, and reliability. These vectors are highly complex, containing variations such as empty capsids, partial genomes, and full-length payloads that directly impact safety, potency, and consistency.

Emerging analytical technologies are addressing these limitations by enabling simultaneous, high-resolution measurement of multiple critical quality attributes in a single workflow. By analyzing both capsid structure and genetic payload together, these platforms provide a more complete understanding of vector composition, reducing variability between assays and improving confidence in results.

This deeper level of insight supports faster process development, earlier detection of quality risks, and more informed decision-making throughout the manufacturing lifecycle. As regulatory expectations evolve toward data-rich, quality-by-design approaches, advanced analytics are becoming essential tools for accelerating timelines and ensuring robust, compliant gene therapy production.